CD19 and precursor B-cell acute lymphoblastic leukemia: At Memorial Sloan Kettering Cancer Center (MSKCC), researchers achieved significant breakthroughs by successfully treating aggressive B-ALL in experimental mouse models, utilizing a modified second-generation CD19 CAR incorporating CD3ζ signaling and CD28 co-stimulation mechanisms [247].